Zydus Lifesciences · NSE: ZYDUSLIFE · BSE: 532321

Q3 FY23 results · Oct–Dec 2022

Zydus Lifesciences reported revenue from operations of ₹4,362.30 crore (up 19.4% from Q3 FY22) and net profit of ₹631.20 crore (up 23.6% from Q3 FY22) for Q3 FY23 (Oct–Dec 2022), on a consolidated basis.

Consolidated · ₹ crore
Item	Q3 FY23	Q3 FY22	YoY	Q2 FY23	QoQ
Revenue from operations	4,362.30	3,655.00	+19.4%	4,134.70	+5.5%
Other income	38.50	60.80	−36.7%	44.40	−13.3%
Total income	4,400.80	3,715.80	+18.4%	4,179.10	+5.3%
Profit before share of associates & JVs and tax	780.10	599.00	+30.2%	642.80	+21.4%
Share of profit/(loss) of associates & JVs	45.90	22.30		14.80
Net profit for the period	631.20	510.60	+23.6%	526.10	+20.0%
Attributable to shareholders of the company	622.90	500.40	+24.5%	522.50	+19.2%
EPS, basic (₹)	6.15	4.89	+25.8%	5.15	+19.5%
Net margin (%)	14.5	14.0		12.7

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q3 FY23	Q3 FY22	YoY	Q2 FY23	QoQ
Revenue from operations	2,086.90	1,830.30	+14.0%	2,398.80	−13.0%
Other income	136.30	25.90	+426.3%	109.20	+24.8%
Total income	2,223.20	1,856.20	+19.8%	2,508.00	−11.4%
Profit before tax	384.80	239.90	+60.4%	600.10	−35.9%
Net profit for the period	255.90	197.00	+29.9%	451.10	−43.3%
EPS, basic (₹)	2.53	1.92	+31.8%	4.45	−43.1%
Net margin (%)	12.3	10.8		18.8

Consolidated

Filed with BSE: 03 Feb 2023, 17:12 IST
Board meeting: 03 Feb 2023
Period: 01 Oct 2022 to 31 Dec 2022
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 03 Feb 2023, 17:12 IST
Board meeting: 03 Feb 2023
Period: 01 Oct 2022 to 31 Dec 2022
Review status: Unaudited
Source: XBRL filing on BSE